Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	ovarian cancer
ICD-0-3	C56.9
Methods	qPCR, Cell proliferation assay, Flow cytometric assay, Luciferase reporter assay, etc.
Sample	Three human OC cell lines (HEY, SKOV-3, OVCAR-3), normal human ovary cell line (IOSE80). OC tissues.
Expression Pattern	up-regulated
Function Description	Taken together, our finding shows that PVT1 may be a novel biomarker for prognosis and a promising therapeutic target for OC.Patients were divided into high PVT1 expression group and low PVT1 expression group on the basis of the median of PVT1 expression levels in OC tissues. Kaplan-Meier survival analysis and log-rank test were used to evaluate the correlation between PVT1 expression levels and overall survival rate of OC patients. P < 0.05, *P < 0.01.Mechanistically, miR-133a was identified to serve as a direct downstream target of PVT1 in OC. Knockdown of PVT1 inhibited cell proliferation, migration and invasion through negative regulating miR-133a in OC cells.The long non-coding RNA, plasmacytoma variant translocation 1 (PVT1), was reportedly to be highly expressed in a variety of tumors including ovarian cancer (OC).
Pubmed ID	29957467
Year	2018
Title	Long non-coding RNA PVT1 promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer.

External Links